Asset Details
Do you wish to reserve the book?
Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
Do you wish to request the book?
Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
2016
Overview
Objectives. To observe changes in blood glycemic variations and oxidative stress level before and after dapagliflozin treatment in patients with newly diagnosed T2DM. Methods. This was a randomized, double-blind, placebo-controlled, phase 3 trial. A total of 28 patients with newly diagnosed T2DM with H b A 1 c levels of 7.5–10.5% were randomly selected to receive dapagliflozin or placebo treatment for 24 weeks. After baseline data were collected, we analyzed glycemic variations and plasma 8-iso PGF2α level at baseline and at the endpoint. Primary outcome was the changes of mean amplitude glycemic excursion (MAGE) within groups. Results. After 24-week dapagliflozin therapy, our data showed the significant improvement of MAGE with dapagliflozin therapy ( P = 0.010 ). Compared with control group, patients in dapagliflozin group exhibited reduction in 24-hour MBG ( P = 0.026 ) and lower mean plasma glucose concentrations, especially during periods from 2400 to 0200 and 1300 to 1800 ( P < 0.05 , resp.). In addition, plasma 8-iso PGF2α level was notably decreased in the treatment group compared to the control group ( P = 0.034 ). Conclusions. In conclusion, this study shows the ability of dapagliflozin to improve glycemic variations and associate with reduction of oxidative stress in patients with T2DM, which may benefit the cardiovascular system.
Publisher
Hindawi Publishing Corporation,John Wiley & Sons, Inc,Wiley
Subject
/ Benzhydryl Compounds - therapeutic use
/ Diabetes
/ Diabetes Mellitus, Type 2 - drug therapy
/ Diabetes Mellitus, Type 2 - metabolism
/ Dinoprost - analogs & derivatives
/ Fasting
/ Glucose
/ Glucosides - therapeutic use
/ Glycated Hemoglobin - metabolism
/ Humans
/ Hypoglycemic Agents - therapeutic use
/ Plasma
/ Sensors
